ПОЛИКИСТОЗ ТУХУМДОН СИНДРОМИ ФОНИДА ТГСС: ДАВОЛАШ ХУСУСИЯТЛАРИ ВА АСОРАТЛАР ПРОФИЛАКТИКАСИ (АДАБИЁТЛАР ШАРҲИ)
Keywords:
тухумдонлар гиперстимуляция синдроми; ЁРТ; овариал стимуляция; асцит;Abstract
Реабилитация даврида симптомлар регрессиясигача динамик УТТ/лаборатор назорат, тромбоз хавфини баҳолаб профилактикани давом эттириш, келгуси цикллар учун қайта риск-стратификация ва психологик қўллаб-қувватлаш муҳим ҳисобланади. Манбалар рўйхати халқаро клиник қўлланмалар ва тизимли шарҳлар асосида тузилди.
References
1. Practice Committee of the American Society for Reproductive Medicine. (2024). Prevention of moderate and severe ovarian hyperstimulation syndrome: A guideline. Fertility and Sterility, 121(2), 230–245. doi:10.1016/j.fertnstert.2023.11.013
2. Tsampras, N., Palinska-Rudzka, K., Alebrahim, Y., Craciunas, L., & Mathur, R. (2025). Prevention of ovarian hyperstimulation syndrome (OHSS): British Fertility Society policy and practice guideline. Human Fertility (Cambridge), 28(1), 2441827. doi:10.1080/14647273.2024.2441827
3. Royal College of Obstetricians and Gynaecologists. (2016). The management of ovarian hyperstimulation syndrome (Green-top Guideline No. 5). London: RCOG.
4. Tan, S. L., & Mathur, R. (2013). The management of ovarian hyperstimulation syndrome. Human Fertility (Cambridge), 16(3), 160–161. doi:10.3109/14647273.2013.844682
5. The ESHRE Guideline Group on Ovarian Stimulation. (2020). ESHRE guideline: Ovarian stimulation for IVF/ICSI. Human Reproduction Open, 2020(2), hoaa009. doi:10.1093/hropen/hoaa009
6. Tang, H., Hunter, T., Hu, Y., et al. (2021). Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews, 2021(5), CD008605. doi:10.1002/14651858.CD008605.pub4
7. Youssef, M. A. F. M., et al. (2014). Gonadotropin-releasing hormone agonist versus hCG for oocyte triggering in antagonist-assisted reproductive technology cycles. Cochrane Database of Systematic Reviews, 2014(10), CD008046. doi:10.1002/14651858.CD008046.pub4
8. Leitao, V. M., Moroni, R. M., Seko, L. M., Nastri, C. O., & Martins, W. P. (2014). Cabergoline for the prevention of ovarian hyperstimulation syndrome: Systematic review and meta-analysis. Fertility and Sterility, 101(3), 664–675.
9. Wormer, K. C., Jangda, A. A., El Sayed, F. A., Stewart, K. I., Mumford, S. L., & Segars, J. H. (2018). Is thromboprophylaxis cost effective in ovarian hyperstimulation syndrome: A systematic review and cost analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology, 224, 117–124. doi:10.1016/j.ejogrb.2018.03.028
